Literature DB >> 8818558

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

J Koo1.   

Abstract

With the changing health care scene in the United States, it is important to have up-to-date epidemiological data with regard to the prevalence of psoriasis in the United States. It is also becoming more important to develop a psychometric instrument that is useful in assessing quality of life issues among psoriasis patients. The Psoriasis Disability Index, which was developed in England, may not be optimally applicable in assessing quality of life issues among psoriasis patients seen by American dermatologists. In this article, the latest nationwide population-based epidemiologic data on psoriasis are presented, along with the use of a new psychometric questionnaire that emphasizes the assessment of quality of life rather than disability.

Entities:  

Mesh:

Year:  1996        PMID: 8818558     DOI: 10.1016/s0733-8635(05)70376-4

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  62 in total

1.  Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol. In the treatment of mild to moderate plaque psoriasis.

Authors:  D M Ashcroft; A Li Wan Po; H C Williams; C E Griffiths
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

3.  The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?

Authors:  Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

4.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.

Authors:  N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2011-02-03       Impact factor: 9.302

Review 5.  Clinical and histologic diagnostic guidelines for psoriasis: a critical review.

Authors:  Mary Ann N Johnson; April W Armstrong
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

6.  Sleep Quality and its Association with Disease Severity in Psoriasis.

Authors:  Mehmet Melikoglu
Journal:  Eurasian J Med       Date:  2017-06

7.  Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.

Authors:  Chuanpu Hu; Bruce Randazzo; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-20       Impact factor: 2.745

8.  Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis.

Authors:  Ivan Nestorov; Ralph Zitnik; Thomas Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

9.  Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.

Authors:  Ivan Nestorov; Ralph Zitnik; Todd DeVries; Arline M Nakanishi; Andrea Wang; Christopher Banfield
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

10.  A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

Authors:  Chuanpu Hu; Zhenling Yao; Yang Chen; Bruce Randazzo; Liping Zhang; Zhenhua Xu; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-16       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.